Aggression  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT01538641: Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Completed
2
43
US
Rituximab, Gemcitabine, Oxaliplatin
Auxilio Mutuo Cancer Center
Refractory Aggressive Non-Hodgkin's Lymphoma, Relapsing Aggressive Non-Hodgkin's Lymphoma
08/07
12/08
RGemOx, NCT01562977 / 2008-007305-36: Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Completed
2
82
Europe
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
04/15
04/15
NCT00472849: Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Checkmark aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
Jul 2013 - Jul 2013: aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
Checkmark P1/2 data release
Jun 2011 - Jun 2011: P1/2 data release
Completed
1/2
92
US
Oxaliplatin, Fludarabine, Fludara, Cytarabine, Cytosar, Ara-C, Rituximab, Rituxan, Pegfilgrastim, Neulasta
M.D. Anderson Cancer Center, Sanofi
Richter's Transformation, Leukemia
02/12
02/12

Download Options